The bio-availability of the DPP-4 inhibitors is very good and the pharmacodynamic- as well as the pharmacokinetic characteristics lead to the above mentioned clinically sufficient DPP-4 inhibition with once daily dosing (only vildagliptin has to be dosed twice daily) (18, 19)
The primary antibodies employed were: P53 (Proteintech, 60283-2-Ig), pSer46-P53 (CST, 2521), FOXO4 (Proteintech, 21535-1-AP), P21 (CST, 2947), P16 (CST, 18769), BAX (CST, 2772), BCL2 (CST, 3498), Ki-67 (Proteintech, 84192-4-RR), Lamin B (CST, 13435), Cleaved Caspase 3 (CST, 9664), -H2AX (Abcam, ab81299), and GAPDH (Abcam, ab8245) as an internal reference for normalizing protein expression levels
28 Talal YounesSMaedaKJSasserJRyanMJ
Another issue is timing
Ipamorelin doses in human studies have ranged from 200 to 600 mcg per injection subcutaneously